OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
2.050
+0.090 (4.59%)
At close: Aug 13, 2025, 4:00 PM
2.100
+0.050 (2.44%)
Pre-market: Aug 14, 2025, 9:02 AM EDT
OmniAb Revenue
OmniAb had revenue of $3.90M in the quarter ending June 30, 2025, a decrease of -48.82%. This brings the company's revenue in the last twelve months to $23.03M, up 6.05% year-over-year. In the year 2024, OmniAb had annual revenue of $26.39M, down -22.75%.
Revenue (ttm)
$23.03M
Revenue Growth
+6.05%
P/S Ratio
9.33
Revenue / Employee
$201,991
Employees
114
Market Cap
251.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OABI News
- 7 days ago - OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 4 weeks ago - OmniAb to Report Second Quarter 2025 Financial Results on August 6 - Business Wire
- 3 months ago - OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit - Business Wire
- 3 months ago - OmniAb, Inc. (OABI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - OmniAb Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - OmniAb Introduces the xPloration® Partner Access Program - Business Wire
- 3 months ago - VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewsWire